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Electronic cigarettes are a frequently debated topic in public health. It is essential that clinical 
trials examining e-cigarettes are fully and accurately reported, especially given long-standing 
concerns about tobacco industry research. We assess the reporting of clinical trials sponsored 




We searched ClinicalTrials.gov for all trials sponsored by Juul Labs Inc. and determined 
those with registry data consistent with coverage by the FDA Amendments Act 2007 
(FDAAA). For trials with a primary completion date more than one year earlier, we searched 
ClinicalTrials.gov, the academic literature, and a Juul-funded research database (JLI Science) 
for results. For located results we compared reported outcomes to registered outcomes in line 
with CONSORT reporting guidelines. 
 
Results 
We located five registered trials sponsored by Juul Labs Inc. that appeared covered by the 
FDAAA 2007 in the public data. All five trials did not have results available on 
ClinicalTrials.gov. We found one publication and four poster presentations reporting results 
for four of the five covered trials outside of ClinicalTrials.gov. Of 61 specified outcomes, just 




Our findings raise substantial concerns regarding these trials. Clinicians, public health 
professionals, and the public cannot make informed choices about the benefits or hazards of 
e-cigarettes if the results of clinical trials are not completely and transparently reported. 
Clarification and potential enforcement of reporting laws may be required.  
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What this paper adds 
● Reporting biases can lead to distortions of evidence. Without complete and timely 
reporting of clinical trials, stakeholders are left without the best possible evidence to 
inform their decision-making. Clinical trial registries provide a key tool for 
investigating accountability in preventing biases. 
● Despite considerable attention paid to e-cigarette research, and longstanding concerns 
about industry funded tobacco research, we could locate no prior work specifically 
investigating reporting biases among registered e-cigarette industry sponsored 
research. 
● Our results show that Juul Labs Inc., the largest e-cigarette manufacturer in the US, 
has not completely reported their sponsored clinical research, including a failure to 
report any results to ClinicalTrials.gov. This piece provides an examination of how 
outcome reporting biases manifest in the published accounts of trials when compared 






E-cigarette manufacturers’ compliance with clinical trial reporting expectations: a case 
series of all registered trials by Juul Labs, Inc. 
 
Background 
Electronic nicotine delivery systems (ENDS, or e-cigarettes) are controversial. Some see 
them as an important weapon in the struggle against smoking.[1] Others question their real 
world effectiveness as quitting aids, their short and long-term safety, and their role in 
promoting nicotine addiction.[2,3] Over 40 countries have banned the sale of e-cigarettes, 
with others restricting marketing.[4] In early 2020 the US Government banned most 
flavoured e-cigarette cartridges amid concerns about uptake in non-smoking teenagers.[5] 
Given these ongoing questions, it is essential that e-cigarette research is made fully available 
in a timely manner to inform medical and public health decision-making.  
 
The importance of complete reporting of clinical trial results is recognized by international 
bodies.[6,7] In the US, the FDA Amendments Act (FDAAA) 2007 and its 2017 Final Rule 
requires the sponsors of certain trials to report results within one year of primary completion 
directly to the ClinicalTrials.gov registry.[8,9] However, it is not sufficient simply to report: 
reporting trials accurately is promoted by guidelines such as CONSORT, which aims to 
improve the reporting of clinical trials through “complete, clear, and transparent information 
on its methodology and findings” and is endorsed by over 500 academic journals.[10]  
Protocols and trial registrations should be published prospectively to avoid undisclosed 
“outcome-switching” and selective non-reporting which can exaggerate benefits and 
obfuscate harms of interventions.[11–13] 
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In an August 2019 commentary, Tan and colleagues raised concerns about industry 
sponsored vaping research.[14] They focus on JLI Science, a Juul Labs, Inc. (Juul Labs) 
research centre, that supports e-cigarette studies. Juul Labs is a major e-cigarette company 
holding 27% of the US market share in 2017.[15] Tan and co-authors noted a lack of 
transparency around JLI Science’s funding mechanisms, research processes, and potential 
conflicts of interest. When auditing the JLI Science website the authors could not locate 
details on governance, funding, study selection, and reporting of Juul Labs-supported 
research that would allow proper assessments of influence. These findings raise concerns that 
research arising from this centre may be used to “positively portray the tobacco industry and 
lobby against regulatory actions” as has occurred in the past. Examining these transparency 
concerns has only grown in importance given the June 2020 Premarket Tobacco Product 
Application submission to the US Food and Drug Administration (FDA) by Juul Labs that 
relies on their “comprehensive research program...examining the public health impact of the 
JUUL System.”[16] 
 
We therefore set out to examine whether results of e-cigarette clinical trials sponsored by Juul 
Labs were reported by international standards on trial reporting timelines and the CONSORT 




We searched ClinicalTrials.gov for all interventional clinical trials in which Juul Labs was 
the primary sponsor. We assessed whether each trial had data fields consistent with coverage 
under the FDAAA 2007, based on established inclusion logic derived from official 
documentation.[8,17–20] The “FDA-regulated Device Product” field, added to 
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ClincialTrials.gov when the Final Rule came into effect, denotes coverage by device 
regulations and is used to aid determinations of whether FDAAA reporting requirements 
apply to a given trial.[19,20] As with all information on ClinicalTrials.gov, this field is 
attested to as accurate by the sponsor and reviewed in quality control by ClinicalTrials.gov 
staff before being made publicly available.[8,21] While official determination of coverage 
under FDAAA would not solely be based on registered data elements, the use of 
ClinicalTrials.gov data for public audit of potential FDAAA coverage is expressly 
encouraged in the Final Rule preamble (“Public users of ClinicalTrials.gov, other than 
responsible parties, should be able to understand whether a registered trial is an applicable 
clinical trial”) and has informed prior analyses.[17,22,23] 
 
Aligned to both the FDAAA 2007 and accepted ethical standards, we expected results to be 
available within one year from primary completion both on ClinicalTrials.gov and via any 
other dissemination routes.[6,24]  
 
Results Searches 
To assess each trial’s reporting status two authors (NJD, HMD) searched 1) 
ClinicalTrials.gov 2) the academic literature via PubMed and Google Scholar and 3) the JLI 
Science “Research Library” database (https://jliscience.com/research-library). For searches 
outside ClinicalTrials.gov the trial ID, principal investigator (PI), and keywords derived from 
the trial title and design were used as search terms. Publications of results were matched to 
registrations using either the presence of a trial ID or a comparison of the study aims, 
authors/affiliations, design, sample size, and outcomes. Each assessor independently 
compared reported results with the currently specified outcomes on ClinicalTrials.gov, based 
on CONSORT items 6 (i.e., disclose changes to trial outcomes), 17 (i.e., report all outcomes) 
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and 18 ( i.e., identify non-specified analyses performed).[10] Changes from the prespecified 
outcomes to current outcomes on the registry, obtained via the ClinicalTrials.gov archive site, 
are noted. 
 
Each outcome was classed as: “fully reported;  “reported with issues” where there was a 
substantial undeclared deviation from how an outcome was specified; “properly declared” if  
unreported or changed, but with disclosure; “unreported” if it was not located; or “unclear” if 
it could not be assessed. Findings from searches and outcome assessments were discussed in 
committee and discrepancies resolved by consensus. We narratively report our assessments 
including any issues with outcome reporting and justifications for certain assessments. We 
provide summary statistics on our search results and outcome assessments. All assessment 




On 1 August 2020, searching ClinicalTrials.gov for “Juul Labs, Inc”, the standardised 
sponsor name for the company on ClinicalTrials.gov, returned 11 registrations. We excluded 
one trial (NCT04452175) because Juul Labs was a collaborator, not the primary sponsor. 
Five further trials were excluded as their registrations were inconsistent with potential 
FDAAA coverage (NCT04143256, NCT04123041, NCT04107779, NCT04088175 & 
NCT03700112). None of these excluded trials had results available on ClinicalTrials.gov, and 
only NCT03700112 was completed for over a year as of 1 August 2020 and could have been 
included. Table 1 includes the title and primary completion dates (PCD) for all excluded 
trials with additional information is available in the appendix. 
Table 1 - Details of Excluded Trials 
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An Open-Label, Multi-Center Study to Evaluate Selected 
Constituents in the Exhaled Breath Samples From the Use of JUUL 
Nicotine Salt Pod System Product (5% and 3% Virginia Tobacco, 
Mint, Mango, Menthol) Users and Conventional Cigarettes (Non-
Menthol and Menthol Flavors) 12 December 2019 
NCT04123041 
A Randomized, Open-Label, Cross-Over Study to Characterize the 
Nicotine Uptake and Subjective Effects With Use of JUUL 
Electronic Nicotine Delivery Systems With Multiple Flavors and 
Nicotine Concentrations, Usual Brand of Combustible Cigarettes, a 
Comparator E-Cigarette and Nicotine Gum in Adult Smokers 18 December 2019 
NCT04107779 
A Randomized, Open Label, Parallel Group Study in Adult Smokers 
to Evaluate Changes in Biomarkers of Cigarette Smoke Exposure 
After Switching Either Exclusively or Partly to Using JUUL 
Electronic Nicotine Delivery Systems With Two Different Nicotine 
Concentrations 17 February 2020 
NCT04088175 
A Randomized, Open-Label, Cross-Over Study to Characterize 
Puffing Topography With Use of JUUL Electronic Nicotine Delivery 
Systems (ENDS) in Adult, Closed-System ENDS Consumers 23 January 2020 
NCT03700112 
An Open Label, Randomized Crossover Study Comparing Nicotine 
Pharmacokinetics of Seven Electronic Cigarette Products and One 
Traditional Cigarette Across Two Delivery (10 Puff and Ad-libitum) 
Conditions, in Healthy Adult Smokers. 24 February 2019 
NCT04452175 
Cigarette Consumption After switchinG to High or Low Nicotine 
strENght E-cigaretteS In Smokers With Schizophrenia (GENESIS) March 2022 
 
Five trials were registered consistent with the Final Rule’s “Applicable Clinical Trial” (ACT) 
criteria.[17,20] All are interventional and affirm they are on an “FDA-regulated Device 
Product”.[18] It was not immediately apparent why Juul Labs inconsistently identified similar 
trials as being on FDA-regulated products. The meaning of this field is not ambiguous in 
ClinicalTrials.gov materials [19,20] and since data on ClinicalTrials.gov, especially those 
relating to FDAAA coverage, are attested to as accurate on submission, we maintained our 
original inclusion/exclusion criteria in line with the public data. Results were expected for all 
five trials as the PCD was more than one year ago as of 1 August 2020. Table 2 includes the 
key dates for each included trial. 
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Searches were conducted in August 2020. None of the five trials had results reported to 
ClinicalTrials.gov. We located conference posters containing results for four of the five trials 
on the JLI Sciences website and one publication in the literature reporting more in depth 
results from one of the posters. Three of the posters were available under a year from the 
provided primary completion date. Details of available results and outcome discrepancies are 





This study examined “biomarkers of exposure” across various tobacco products including 
four Juul products. There were no meaningful changes to outcomes after first registration, 
however this trial was retrospectively registered by three days (Table 2) while the follow-up 
for the primary outcomes was just five days. 
 
We located two results outside of ClinicalTrials.gov: a poster presented at the 25th Annual 
Meeting of the Society for Research on Nicotine and Tobacco on 23 February 2019 and 
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available on the JLI website; [25] and an article published online in the journal Nicotine & 
Tobacco Research on 5 November 2019.[26] As of writing, Nicotine & Tobacco Research 
has not endorsed the CONSORT guidelines.[27] The paper includes all the outcomes 
reported in the poster in addition to adverse events and a declaration that the three 
pharmacokinetic outcomes would be reported in a future publication. Across both 
publications: the primary outcome was fully reported; six (32%) of the 19 secondary 
outcomes were fully reported; five (26%) were reported with issues; three (16%) were not 
reported but properly declared; and one (5%) was unclear, leaving four (21%) entirely 
unreported.  
 
Of the five outcomes reported with issues, four were measures of nicotine equivalents in the 
urine (nicotine, cotinine, trans-3'-hydroxycotinine, and Glucuronides) that were specified 
separately but reported as a grouped measure;  the other was measuring “future intent to use” 
which specified no specific scale in the registry then reports the brief Wisconsin Inventory of 
Smoking Dependence Motives (WISDM). WISDM includes some aspects that could be 
indicative of “intent to use” in combination with non-prespecified measures of 
dependence.[28] 
 
The three secondary outcomes related to nicotine equivalents measured in the blood are noted 
in the paper’s methods but could not be located anywhere in the results or appendices. 
Product malfunctions were grouped with adverse events. While no malfunctions were listed, 
there was no statement to confirm that none occurred despite being listed as a discrete 




This was an open label study to examine emissions across three different environments for a 
Juul device, a competitor device (Vuse solo), and conventional cigarettes. Carbon monoxide 
(CO) was removed from two outcomes on 18 September 2018, the day after the provided 
start date. No results were found on ClinicalTrials.gov. 
 
Searches revealed no results in the academic literature. The JLI Science website contains a 
poster presented at the 6th Annual Global Forum on Nicotine on 14 June 2019.[29] Of the 12 
prespecified primary outcomes on ClinicalTrials.gov eight (67%) are fully reported, two 
(17%) have issues with their reporting based on the components specified in the outcome, 
and two (17%) are not reported. 
 
In the poster, outcomes describing “room air samples” were not consistently and clearly 
reported for both use conditions despite identical specification in the registry entry. Select 
carbonyls in exhaled breath (acetaldehyde and acrolein) were not reported. Propylene glycol 
in exhaled breath is mentioned in the results text as “elevated” with reference to “Figure 2”, 
but does not appear in “Figure 2” and is therefore considered unreported. Exhaled CO is 
reported in the poster but room air CO is not; both were removed as outcomes on 
ClinicalTrials.gov. Lastly, measurements on particle size are missing for one of the 
group/setting pairs with no explanation.  
 
NCT03593239 
This study intended to examine the nicotine pharmacokinetics of various Juul 1.7% and 5% 
nicotine salt products across four primary and two secondary outcomes. No outcome 
definitions meaningfully changed from first registration. Searches revealed no results in the 




This study assessed “puff topography” (PT) in adult smokers using the “Juul 5% Electronic 
Nicotine Delivery Systems” product. No outcome definitions meaningfully changed from 
first registration. 
 
Searches revealed no results in the academic literature. The JLI Science website contains a 
poster with results presented at the 6th Annual Global Forum on Nicotine on 14 June 
2019.[30] All five (100%) primary outcomes are reported, however only two of the seven 
(29%) secondary outcomes are reported. The “self-reported product use” secondary outcome 
was conservatively determined to be fully reported despite slight differences in how 
consumption was measured compared to the prespecified outcome. The five unreported 
secondary outcomes were subjective measures, specifically: cigarette dependence, smoking 




This study examined the nicotine pharmacokinetics of various Juul 5% nicotine salt products, 
Vuse Solo e-cigarettes, Nicorette 4mg nicotine gum, and standard combustible cigarettes. The 
primary outcomes were vaguely specified pharmacokinetic measurements of nicotine uptake 
in the plasma referencing a statistical analysis plan (SAP) that could not be located. No 
outcome definitions meaningfully changed from first registration. 
 
We located no results searching the academic literature but found a matching poster on the 
JLI Science website from the 2020 Annual Meeting of the Society for Research on Nicotine 
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& Tobacco on 14 March 2020.[31] The primary outcome was reported however just two 
(20%) of the 10 secondary outcomes were fully reported without issue. One (10%) additional 
secondary outcome was partially reported and seven (70%) were unreported without any 
disclosure. 
 
Various measures were reported that fit the broad “pharmacokinetic parameters” primary 
outcome. While we could not access the SAP we conservatively counted it as fully reported 
given there were pharmacokinetic details. For one of the secondary outcomes, the complete 
modified Product Evaluation Scale (mPES) was specified but only a single sub-scale 
(“Satisfaction”) was reported. Missing outcomes included measures of blood pressure, heart 
rate, product usage, and two additional subjective scales (Nicotine Withdrawal Questionnaire 
and Product Direct Effect Questionnaire). 
 
Summary of Results 
All trials assessed did not report results on ClinicalTrials.gov. Only one of five trials had any 
results reported in the academic literature, but with notable inconsistencies. Four trials were 
reported in conference posters shared on the JLI Science website: these provide only brief 
methods and none completely reported all prespecified outcomes with no disclosure 
regarding altered outcomes or additional results available elsewhere.  
 
Overall just 28 of 61 (46%) prespecified outcomes across all five trials were reported or 
properly declared, and 8 (13%) additional outcomes were reported but with issues; by 
outcome type 15 of 23 (65%) primary outcomes and 13 of 38 (26%) secondary outcomes 
were accounted for in any results reports. Problematic outcomes were either examining 
specific levels of molecules arising from tobacco use in various contexts (e.g., urine, breath, 
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room air, plasma) or subjective measures. Among the eight outcomes reported with issues, 
six measured specific molecules and two were subjective scales and among the 24 missing 
outcomes, 11 were examining molecule concentrations and nine were subjective measures.  
Summary results for outcome assessments are presented in Table 3. Detailed annotations for 
all outcome assessments are provided in supplementary material. 
 
Table 3 - Reporting of Juul Sponsored Clinical Trials 
Measure NCT03463837 NCT03605641 NCT03593239 NCT03596034 NCT03719391 
Total 
(%) 
Results reported on 
ClinicalTrials.gov 




Yes (Poster & 
Paper) 







1 12 4 5 1 23 
Number of primary 
outcomes fully 
reported 
1 (100%) 8 (67%) 0 5 (100%) 1 (100%) 
15 
(65%) 
Number of primary 
outcomes partially 
reported 




required to report 









reported with issues 







declared 3 (16%) 0 0 0 0 3 (8%) 




Non-reporting and selective outcome reporting are well documented sources of bias in 
clinical research.[11,17,32] Prior work assessing registrations consistent with FDAAA 
coverage found 74% of industry-sponsored trials and 63% of non-industry-sponsored trials 
had reported results at any time after becoming due.[17] Another prior investigation by our 
team on selective outcome reporting at top medical journals found that among 67 trial 
manuscripts with 915 specified outcomes, 524 (57.2%) were reported correctly and an 
additional 5 were reported but switched between primary and secondary designations.[33] 
Other studies have consistently shown more complete reporting of results to 
ClincialTrials.gov compared to journal articles.[34–37] 
 
We are aware of the longstanding research literature on financial conflicts of interest and 
concerns around the poor quality and selective publication of tobacco-industry research.[38–
40]  Recent reviews have concluded that conflicts of interest are an important factor in 
interpreting the findings of e-cigarette research.[41,42] Many journals have policies to not 
publish research sponsored by the tobacco industry due to their notable history of past 
research distortion and misconduct.[43–45] Given this history, tobacco-industry funded e-
cigarette research may be of questionable scientific value. Still, the fact remains that these 
trials occurred and may be used as evidence in regulatory proceedings. It is important that the 
trials are reported fully and transparently in line with best practices so that they can be 
critically interpreted, assessed for potential bias, and properly considered in full by the 
broader medical and public health community, as with all trials research.  
 
Results disseminated through JLI Science, in the form of conference posters with space 
limitations, cannot be counted on to convey complete results which may complicate or bias 
their inclusion in future evidence synthesis. ClinicalTrials.gov provides a robust 
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dissemination route, independent of journals and without space restrictions, in which this 
research can be freely shared. While this route lacks peer review and some methodological 
detail it also provides clear summary statistics, with minimal potential for narrative spin, in a 
standard discoverable format.  
 
Reasons for non-reporting can vary substantially.[46] Juul Labs has sponsored relatively few 
registered trials: prior work has shown reporting under FDAAA requirements increases with 
more sponsored trials on ClinicalTrials.gov; it is possible that more experienced sponsors 
have deeper knowledge of their obligations, ethical or legal, and can implement more robust 
reporting practices and expectations at scale.[17] It should be noted, however, that Juul Labs 
is part owned by Altria, formerly Philip Morris, a major tobacco company with an established 
research programme.[14] We cannot speculate on what the unreported results from these 
clinical trials may be or why they occurred; prior research shows that trials with less 
favourable results overall are less likely to reported;[47] and that even within reported trials, 
non-significant outcomes are less likely to be reported.[48] These are the very issues that 
FDAAA 2007 set out to address.[9] 
 
Strengths and Limitations 
In reporting detailed examinations of each trial’s outcomes, we aimed to provide both insight 
into our evaluations and concrete examples of how outcome reporting bias occurs in the 
literature. Many studies have summarised the issue of outcome reporting bias and established 
it as an issue, and we hope this case series offers useful detail and examples of how this can 
occur in practice.[11,33] 
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This work has limitations. As with all studies reliant on bibliographic searches some results 
may exist but were not located. However, per ICMJE and CONSORT best practice, trial IDs 
should be clearly present in the abstracts and text of clinical trial publications.[10,49] If our 
trial ID and keyword searches could not locate relevant publications across multiple 
databases, low discoverability would represent a breach of best practice. 
 
Data accuracy and availability is another potential limitation. Study documents with more 
detail on outcomes may exist. We could not locate any public source of trial protocols or 
SAPs for Juul Labs sponsored research. If changes to outcomes occurred, they should be 
reflected on ClincialTrials.gov and in any publications. Inaccurate or out-of-date data on the 
registry may lead to misclassification based on our inclusion/exclusion criteria and outcome 
evaluations. The availability of posters for four of the five trials further confirms that the 
trials did occur and full results could be made available. We believe sponsors have a clear 
ethical and, in the case of trials covered under FDAAA, legal responsibility to ensure their 
trial registrations are kept up to date and therefore should be held accountable to the public 
information they attest to accurately providing to the registry.[50] While officially 
determining FDAAA coverage may require complex regulatory consideration, we believe 
that, consistent with the Final Rule, public accountability based on registered data on 
ClinicalTrials.gov has an important role to play in improving the quantity and quality of trial 
reporting.  
 
We also note that for the five trials considered, registration data was “Verified” meaning the 
information was reviewed after registration and attested to as accurate. At minimum, it 
appears that incorrect registry data has been consistently provided for some of Juul’s 
registered trials. The confusion caused by similar Juul-sponsored trials having different 
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“FDA-regulated device” status suggests that either the regulatory background of these trials 
varies in ways a public user cannot easily ascertain or that Juul have not properly ensured 
accurate information is being registered on ClinicalTrials.gov. 
 
Policy Implications 
ClinicalTrials.gov provides sponsors with information on registered trials that are likely to be 
covered in the backend PRS system.[19] However proactive public information on coverage 
of specific trials under FDAAA has not occurred. Furthermore, to our knowledge, no fines or 
warning letters for non-reporting under FDAAA have ever been issued by the FDA to any 
sponsor.[17,51] This lack of transparency is unfortunate and can lead to ambiguity about 
which trials are covered, lessening the impact of FDAAA reporting requirements.  
 
There is regulatory consistency around the fact that tobacco products, like ENDS, are 
considered drug/device products in certain circumstances (e.g., smoking cessation 
claims).[52–54] Furthermore, the FDAAA Final Rule is clear that the intent to market a drug 
or device has no bearing on requirements to report the trial results of unapproved and 
uncleared treatments beholden to the law.[24] The FDAAA Final Rule discusses the similar 
dual-regulatory pathway of dietary supplements noting that “a substance characterized by a 
responsible party as a dietary supplement could be considered a ‘drug’ subject to section 505 
of the FDC Act under the applicable drug clinical trial definition if the trial is studying a use 
that meets the drug definition under the FDC Act.”[8]  Similarly, another Final Rule (21 CFR 
Parts 201, 801, and 1100)  notes that coverage as a drug/device vs. a tobacco product would 
depend on aspects of the trial itself that can only be determined after evaluation of the 
“methods and measures” to determine “the purposes for which a product is being 
investigated.”[55] The complexity of these various laws, regulatory pathways, and legal 
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precedents complicate the issue of FDAAA coverage for ENDS products and obstructs public 
transparency and accountability.  
 
This ambiguity is apparent when examining our sample. The uptake of nicotine in the body is 
an important component of nicotine addiction.[56] Three of the five trials in our sample 
examine nicotine biomarkers or pharmacokinetics. Trials excluded from our analysis share 
similar outcomes. It is unclear whether these outcomes aid in making claims about the 
“delivery of a pharmacologically active dose of nicotine” which are generally exempted from 
drug/device regulations, investigate “modified risk tobacco product” designations that allow 
claims relative to other tobacco products outside of drug/device regulations, or fall under 
unapproved or uncleared drug/device rules due to their clinical subject matter and outcomes. 
Additional Juul sponsored trials directly address smoking cessation with relevant outcomes 
like product use, dependency, urge to smoke, and aspects of withdrawal raising similar 
coverage questions. Juul’s inconsistent designations may be the result of similar confusion 
about how to classify these trials. 
 
Clarity here may require a more active approach to FDAAA enforcement. Despite criticisms, 
the FDA has not engaged in direct approaches to enforcing the registration and reporting 
requirements of the FDAAA.[17,57] Previous comments from President Joe Biden have 
shown support for active enforcement of results reporting requirements which may signal 
receptiveness of the current administration to these issues.[58] 
 
Failing general efforts to make FDAAA coverage more definitive to the public, the FDA may 
consider specifically clarifying the reporting responsibilities of tobacco-industry sponsors 
under the law. If registered industry-sponsored clinical research into tobacco products 
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supports various tobacco-specific regulatory pathways, instituting reporting requirements as a 
condition of these applications could bypass complicated FDAAA 2007 considerations 
entirely. The public and the scientific community have a clear interest in ensuring the results 
of research on tobacco products is made fully available and current dissemination routes 
appear lacking. In any case, setting aside legal obligations, we note that there is also a strong 
ethical expectation that all clinical trial results should be reported completely in a timely 
manner and this investigation also shows notable deficiencies in outcome reporting.[6,7]  
 
Conclusion 
We describe issues with reporting of Juul Labs Inc. sponsored clinical trials. No trials 
reported on ClinicalTrials.gov nor fully accounted for all registered outcomes via other 
dissemination routes. The FDA should act to further clarify whether trials of ENDS products 
are covered under the FDAAA and encourage compliance as appropriate. Even in the event 
that these trials are mis-identified as covered under FDAAA, we hope that Juul will consider 
setting a higher standard of transparency and work to voluntarily submit all full results to 
ClinicalTrials.gov consistent with their registered outcomes.  
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